Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application ...
The doctor beamed onto a health clinic video screen in October to convince the regional health board to ban public clinics in ...
The US Food and Drug Administration approved Gomekli (mirdametinib), from SpringWorks Therapeutics, a kinase inhibitor, for adult and pediatric patients two years of age and older with ...
Q4 2024 Earnings Call Transcript February 11, 2025 Arvinas, Inc. beats earnings expectations. Reported EPS is $-0.63, ...
The World Health Organization wants to tackle inequity and bureaucracy relating to clinical trials. Will its latest guidance make a difference? Anna Volkmer reports During the covid-19 pandemic the UK ...
Q4 2024 Earnings Call Transcript February 7, 2025 Iterum Therapeutics plc beats earnings expectations. Reported EPS is $-0.12, expectations were $-0.24. Operator: Hello, everyone. And welcome to the ...
Texas Attorney General Ken Paxton has launched an investigation into DeepSeek, the upstart Chinese artificial intelligence ...
Moderna’s norovirus vaccine trial placed on FDA hold over reported case of Guillain-Barré syndrome
A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological ...
Two Trump administration nominees with long track records of challenging the medical and public health establishments have ...
Cambridge, Massachusetts – home to Harvard and MIT – was the primary source of Chinese researchers who chose to head home.
Velsipity and Zeposia are both being offered to the NHS at a discount to their ex-VAT list prices of £11,000 and £17,910 per person, per year, according to NICE guidance documents. Pfizer’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback